BioSpace News Archive

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is highlighting the importance of developing new therapeutic solutions for autism spectrum disorder (ASD) following a new study showing autism is on the rise among young children.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announces its year-end 2022 update on operations following the filing of its audited Financial Statements

Lucius Partners, LLC (“LP”), today announced the filing of two new patent applications to the USPTO by its portfolio company AerWave Medical, Inc.

Biodexa Pharmaceuticals PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to various investors 18,636,190 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 1,738,136 A Warrants and 1,989,102 B Warrants received yesterday.

SkinCure Oncology, provider of GentleCure™, a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy, the most advanced non-surgical technology for the treatment of common skin cancers, announced the elevation of two members of its leadership team to executive posts.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share in the form of American Depositary Shares.

Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full year ended December 31, 2022.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter of Fiscal 2023 on Tuesday, May 2, 2023, prior to the opening of trading on the New York Stock Exchange.